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Abstract
Background: The importance of cell-surface nucleolin in cancer biology was recently highlighted by studies showing 
that ligands of nucleolin play critical role in tumorigenesis and angiogenesis. By using a specific antagonist that binds 
the C-terminal tail of nucleolin, the HB-19 pseudopeptide, we recently reported that HB-19 treatment markedly 
suppressed the progression of established human breast tumor cell xenografts in the athymic nude mice without 
apparent toxicity.
Methods: The in vivo antitumoral action of HB-19 treatment was assessed on the spontaneous development of 
melanoma in the RET transgenic mouse model. Ten days old RET mice were treated with HB-19 in a prophylactic 
setting that extended 300 days. In parallel, the molecular basis for the action of HB-19 was investigated on a melanoma 
cell line (called TIII) derived from a cutaneous nodule of a RET mouse.
Results: HB-19 treatment of RET mice caused a significant delay in the onset of cutaneous tumors, several-months 
delay in the incidence of large tumors, a lower frequency of cutaneous nodules, and a reduction of visceral metastatic 
nodules while displaying no toxicity to normal tissue. Moreover, microvessel density was significantly reduced in 
tumors recovered from HB-19 treated mice compared to corresponding controls. Studies on the melanoma-derived 
tumor cells demonstrated that HB-19 treatment of TIII cells could restore contact inhibition, impair anchorage-
independent growth, and reduce their tumorigenic potential in mice. Moreover, HB-19 treatment caused selective 
down regulation of transcripts coding matrix metalloproteinase 2 and 9, and tumor necrosis factor-α in the TIII cells and 
in melanoma tumors of RET mice.
Conclusions: Although HB-19 treatment failed to prevent the development of spontaneous melanoma in the RET 
mice, it delayed for several months the onset and frequency of cutaneous tumors, and exerted a significant inhibitory 
effect on visceral metastasis. Consequently, HB-19 could provide a novel therapeutic agent by itself or as an adjuvant 
therapy in association with current therapeutic interventions on a virulent cancer like melanoma.
Background
Nucleolin is an abundant DNA-, RNA- and protein-bind-
ing protein ubiquitously expressed in exponentially grow-
ing eukaryotic cells. It is found at several locations in
cells: in the nucleolus it controls many aspects of DNA
and RNA metabolism; in the cytoplasm it shuttles pro-
teins into the nucleus and provides a posttranscriptional
regulation of strategic mRNAs; and on the cell surface it
serves as an attachment protein for several ligands from
growth factors to microorganisms [1-7]. Surface and
cytoplasmic nucleolin are differentiated from nuclear
nucleolin by a slight shift in their isoelectric point, which
could reflect glycosylation of surface/cytoplasmic nucleo-
lin [3,8,9]. Moreover, surface/cytoplasmic nucleolin is
regulated independently of its nuclear counterpart, since
marked reduction of surface/cytoplasmic nucleolin could
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lar localization of nuclear nucleolin [10].
Emerging evidences highlight the importance of the
cell-surface expressed nucleolin in cell proliferation,
tumor cell growth and angiogenesis [3,10-14]. The
enhanced expression of surface nucleolin is observed in
vitro and in vivo in lymphoid organs containing activated
lymphocytes, on the surface of tumor cells and activated
endothelial cells, or in angiogenic endothelial cells within
the tumor vasculature [11,14,15]. Among surface nucleo-
lin binding growth factors and proteins, midkine and
pleiotrophin can transform cells, whereas on endothelial
cells they exert both mitogenic and angiogenic effect [16].
Urokinase that is implicated in mechanisms regulating
pericellular proteolysis, cell-surface adhesion, and mito-
genesis binds and is co-internalized with surface nucleo-
lin [17,18]. Other surface nucleolin binding proteins such
as laminin-1, factor J, L- and P-selectins, and hepatocyte
growth factor are involved in tumor development, induce
cell differentiation, regulate cell adhesion, leukocyte traf-
ficking, inflammation and angiogenesis [19-23]. The
tumor homing peptide F3 that binds both endothelial and
tumor cells is internalized via surface nucleolin, while
endostatin that inhibits angiogenesis binds nucleolin on
the surface of endothelial cells before translocation to the
nucleus [11,13]. Accordingly, the functional blockade or
down-regulation of surface nucleolin in endothelial cells
inhibits migration of endothelial cells and prevents capil-
lary-tubule formation [10,12]. Ligand binding results in
clustering of cell-surface nucleolin in lipid raft membrane
microdomains before endocytosis of the ligand-nucleolin
complex by an active process [5,24,25].
We recently reported that both tumor growth and
angiogenesis could be suppressed by targeting surface
nucleolin using the HB-19 pseudopeptide, which binds
the RGG domain located at the C-terminal tail of nucleo-
lin [10,26]. HB-19 reduced markedly colony-forming
capacity of several human carcinoma cell lines in soft
agar, impaired migration of endothelial cells and forma-
tion of capillary-like structures in collagen gel, and
reduced vessel arborization in the chick embryo chorioal-
lantoic membrane. Significantly, HB-19 treatment mark-
edly suppressed the progression of established human
breast tumor cell xenografts in athymic nude mice, and in
some cases eliminated measurable tumors while display-
ing no toxicity to normal tissue [10].
In a more relevant tumor model, now we provide evi-
dence that HB-19 can also interfere with the spontaneous
development of cancer in RET mice. Such mice express
constitutively an active form of the ret oncogene leading
to development of spontaneous melanoma, thus provid-
ing a genetically driven model of tumors [27]. In this
model the severity grade of melanoma is associated with
the location of skin tumors in which the onset of dorsal
nodules corresponds to a more aggressive disease [28].
The skin primary tumors eventually metastasize mainly
to lymph nodes, mediastinum or lungs [27]. Moreover,
our recent data in this model suggests that the growth of
melanoma involved several tolerance mechanisms [29].
Here we show that HB-19 treatment delays significantly
the onset and frequency of spontaneous melanoma in
RET mice. In addition, the frequency of visceral metasta-
sis and tumor vascularization are significantly reduced in
HB-19 treated compared to control mice, thus indicating
inhibitory effects on both metastasis and angiogenesis.
Using a melanoma cell line derived from a cutaneous
nodule of a RET mouse, we show that HB-19 can affect
several criteria implicated in the tumorigenic potential of
melanoma cells, such as restoration of contact inhibition
in culture, reduction of colony formation in soft agar, and
impairment of tumorigenicity and lung metastasis in
mice. Interestingly, these changes are associated with a
specific inhibitory action of HB-19 on expression of genes
implicated in tumorigenesis.
Methods
Mice
MT/ret+/- transgenic mice (C57BL/6 background, called
RET mice, litter one) expressing the rfp-ret oncogene
develop a spontaneous melanoma [27,30]. Constitutively
activated rfp-ret enhances cRET protein expression in the
process of melanomagenesis in RET mice [31]. Non-
transgenic littermates (MT/ret-/-) were used for trans-
plantation experiments. Mice were maintained in our
own animal facilities corresponding to a pathogen free
environment. All experiments were performed in compli-
ance with French Ministry of Agriculture regulations for
animal experimentation (number 75-510).
HB-19 treatment of RET mice
HB-19 was synthesized as described previously [10,26].
Although it is readily soluble in water, HB-19 was dis-
solved in PBS for the purpose of treatment of mice. Ten
days old RET mice were treated intraperitoneally with
HB-19 at 5 injections/week during week 1-3 and 2 injec-
tions/week during week 4-42. The dose of HB-19 was 50,
100, and 200 μg for the first, second and the rest of the
weeks, respectively. Control mice were injected with PBS
at the different time points. Clinical signs of mice treated
(n = 9) and untreated (n = 11) were assessed once a week
on vigil mice and once a month on anesthetized mice.
Development of facial or dorsal tumor nodules was
recorded. At the end of the treatment (day 300), all mice
were sacrificed and autopsied to monitor for distant
metastasis.
Flow cytometry. Cutaneous tumors were pooled,
mechanically dissociated and digested with 1 mg/mL col-
lagenase A and 0.1 mg/mL DNase I (Roche, Mannheim,
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were filtered, washed in PBS, 5% FCS, 0.5 mM EDTA and
resuspended in RPMI 1640. After incubation with anti-
FcgII/IIIR antibody (clone 2.4G2), cell suspensions were
stained at 4°C, for 15 min with the following combina-
tions of monoclonal antibodies (all from Pharmingen):
PerCP-conjugated anti-CD45.2/APC-conjugated anti-
CD11b and APC-conjugated anti-CD45.2/PE-conju-
gated anti-TcRab. Flow cytometric analyses were per-
formed on a FacsCalibur cytofluorometer (BD
Biosciences) and data were analyzed using CellQuestPro
Software (BD).
Murine melanoma cells and transplantation
The TIII cell-line was derived from the neck cutaneous
nodule that developed in a RET mouse. Cells were cul-
tured in RPMI 1640 with 10% FCS, 2 mM L-glutamine,
100 U/ml penicillin, 100 μg/ml streptomycin. In addition
to the nucleus, nucleolin is also expressed in the cyto-
plasm and at the cell surface of TIII cells, as it is the case
in different types of tumor cells and other melanoma cell
lines [3,32].
TIII (1×106) cells cultured in the presence or not of HB-
19 (10 μM; 12 passages) were transplanted subcutane-
ously in 10 weeks old MT/ret-/- mice. Fourteen days later,
mice were sacrificed and tumor mass was determined
with a caliper. Alternatively, mice were injected in the tail
vein with TIII cells (5×105) in the absence or presence of
10 μM of HB-19. Twenty hours later and then daily dur-
ing two weeks, mice were treated by intraperitoneal injec-
tions of PBS or PBS containing HB-19 (5 mg/kg). Mice
were then sacrificed, and the number of black macro-
metastases on the lung surface was counted.
Immunofluorescence and confocal microscopy
Cells were plated 24 hours before the experiment in
eight-well glass slides (Lab-Tek Brand; Nalge Nunc Inter-
national, Naperville, IL). Cells were fixed with paraform-
aldehyde (PFA; 3.7%, 10 min), permeabilized by Triton X-
100 (0.5%, 15 min) and stained for the intracellular actin
cytoskeleton using FITC-conjugated phalloidin (Sigma)
[10,26]. The nuclei were stained with 4',6-diamidino-2-
phenylindole (DAPI).
Colony formation in soft agar
TIII cells (2×104) were mixed in 0.35% top agar diluted in
RPMI containing 10% FCS in the absence or presence of
different concentrations of HB-19 before plating onto
0.8% bottom agar in 12-multiwell plates. Cells were
treated every two days during 14 days. Colonies with
diameter superior to 100 μm were scored as positive
using a phase contrast microscope equipped with a mea-
suring grid at magnification 50×. The number of colonies
was determined by analyzing 5 fields/well from 3 wells
[10].
Tissue preparation, immunohistochemical staining and 
image analysis
Tumors were fixed in FineFix (Milestone, Bazainville,
France) for paraffin inclusion. Sections of 8 μm thickness
were re-hydrated and saturated in PBS containing 5%
goat serum. Sections were incubated with 1:20 dilution of
a rat anti-mouse CD34 monoclonal antibody (Abcam,
Cambridge, UK) for 2 hours at room temperature. After
two washes in PBS, sections were incubated for 1 hour at
room temperature with biotin-conjugated goat anti-rat
IgG (Chemicon International Inc., Temecula, CA) diluted
at 1:500, followed by three washes in PBS and incubation
with avidin/peroxidase complex (Vector Laboratories,
Burlingame, CA). The horseradish-Peroxidase activity
was revealed by incubating the sections with 3,3'-Diamin-
obenzidine substrate kit (Vector Laboratories). Finally,
the sections were counterstained with haematoxylin, fol-
lowed by water wash and cover slipped with Mowiol
medium. Five microscopic fields (at 200-fold magnifica-
tion) were selected randomly for analysis using the Image
analysis. The density of endothelial cells in each field was
expressed as the ratio of cell area/total area examined ×
100 (%). These values were then averaged for the tumors
recovered from control and HB-19 treated mouse.
mRNA expression monitored by RT-PCR
TIII cells were cultured in RPMI medium containing 10%
FCS in the absence or presence of HB-19. Total RNA was
prepared from cells (5×105) and fresh tumors isolated
from control and HB-19 treated RET mice using RNeasy
Mini Kit (Qiagen) according to the manufacturer's
instructions. RT was carried out with oligo(dT) and 1-4
μg of total RNA using Superscript II RNase H- Reverse
Transcriptase (Gibco BRL). The expression of specific
mRNAs was investigated by RT-PCR using primers for
matrix metalloproteinase-2 and -9 (MMP-2, MMP-9),
vascular endothelial growth factor (VEGF-A), tumor
necrosis factor alpha (TNF-α), signal transducer and acti-
vator of transcription 1 (STAT-1), melanoma inhibitory
activity (MIA), and glyceraldehyde-3-phosphate dehydro-
genase (GAPDH). PCR was performed in a RoboCycler
96 (Stratagene) with the following primers: MMP-2 sense
5'-GAGTTGGCAGTGCAATACCT-3' and antisense 5'-
GCCGTCCTTCTCAAAGTTGT-3'; MMP-9 sense 5'-
AGTTTGGTGTCGCGGAGCAC-3' and antisense 5'-
TACATGAGCGCTTCCGGCAC-3'; VEGF-A sense 5'-
AGAGCAACATCACCATGCAG-3' and antisense 5'-
AGGAATCCCAGAAACAACCC-3'; TNF-α sense 5'-
ACTCCCAGAAAAGCAAGCAA-3' and antisense 5'-
TGGAAGACTCCTCCCAGGTA-3'; STAT-1 sense 5'-
CGTGGGAACGGAAGCATTTG-3 and antisense 5'-
El Khoury et al. BMC Cancer 2010, 10:325
http://www.biomedcentral.com/1471-2407/10/325
Page 4 of 12GAGACATCATAGGCAGCGTG-3'; MIA sense 5'-ATC-
CTATCTCCATGGCTGT-3' and antisense 5'-ACTG-
GCAGTAGAAATCCCA-3'; GAPDH sense 5'-
CGTCCCGTAGACAAAATGGT-3' and antisense 5'-
CCTTCCACAATGCCAAAGTT-3'. PCR amplification
conditions were 95°C for 2 min, 30 cycles at 95°C for 30
sec, 53°C (for MMP-2, VEGF, Mia-1 and GAPDH) or
55°C (for STAT-1) or 57°C (MMP-9) for 30 sec and 72°C
for 45 sec, and this was followed by 5-min incubation at
72°C. The expected RT-PCR product for MMP-2, MMP-
9, VEGF-A, TNF-α, STAT-1, MIA-1 and GAPDH was
666, 754, 663, 688, 425, 267 and 527 base pairs, respec-
tively.
Statistical analysis
Statistical significance was determined by ANOVA
unpaired T test or the Wilcoxon log-rank test using the
GraphPad Prism 4.0 software (San Diego, CA). Values of
p < 0.05 were considered significant.
Results
HB-19 delays significantly development of spontaneous 
melanoma in RET mice
To evaluate the in vivo anti-tumor effect of HB-19 on the
natural course of melanoma progression, RET mice were
treated in a prophylactic setting that extended 300 days as
described in Methods. The particular aspects of the clini-
cal diagnosis of control and HB-19 treated RET mice are
presented individually in Table 1. HB-19 treatment signif-
icantly delayed the development of measurable cutaneous
tumors that occurred at day 50 and 75 in control and
treated mice, respectively (Figure 1A and 1B). The differ-
ence between these two groups was even more significant
when the incidence of large cutaneous tumors (over 60
mm2) was compared (Log-rank test; p < 0.001). Indeed,
large tumors were observed from day 75 onward in con-
trol mice, whereas they started to develop at day 190 in
HB-19 treated mice (Figure 1B). We next examined the
effect of HB-19 on all cutaneous nodules taking account
their location, since our previous observations indicated
that the severity grade of melanoma is associated with the
location of skin tumors, and that in particular the occur-
rence of nodules in the posterior part of the body corre-
sponds to a more aggressive disease [28]. Both facial and
dorsal cutaneous nodules developed later and were less
frequent in HB-19 treated compared to control mice (Fig-
ure 1C and 1D: Log-rank Wilcoxon test, p < 0.001; Figure
1E and 1F p < 0.05). In addition, tumor vascularization
was evaluated by CD34 antigen staining in sections of
tumors recovered from control and HB-19 treated RET
mice (Figure 2). Clearly, numerous vessels remained with
an open lumen in the control samples 'angiogenic hot
spots' localized heterogeneously within the tumor as
compared to HB-19 treated samples. Angiogenesis quan-
tified by image analysis of CD34-labeled endothelial cells
showed that HB-19 induced a reduction of 51% in
microvessel density compared to control tumors.
It is worthwhile to note that two regressions were
observed in the HB-19 treated mouse N°2 and concern
tumors localized under the eye and thigh (Table 1), while
no regression occurred in the control group. Neverthe-
less, we cannot conclude that these regressions are
induced by the treatment although spontaneous regres-
sions are extremely rare in the RET model. Interestingly,
at the end of the experiment two out of nine HB-19
treated mice (mouse N°4 and 6) were still tumor free at
autopsy, and that mouse N°5 displayed no melanoma
symptom at 7.5 months of age, whereas all control mice
bore tumors (Table 1). Of note, the absence of cutaneous
tumors is extremely infrequent in the RET mouse model.
Indeed, in a similar group of 10 month old RET mice in
our animal house facility, only one mouse out of 73 was
free of cutaneous nodules. Finally, 8 out of 11 control
mice had either retroperitoneal metastasis or mediastinal
adenopathies, whereas only 3 out of 9 HB-19 treated ani-
mals (mouse N°1, 2 and 3) displayed visceral or lung
metastasis (Table 1). Therefore, distant metastasis tends
to be less frequent in the HB-19 treated compared to the
untreated group (Table 1; p = 0.09). We have recently
observed that myeloid (CD11b+) and T (TCRαβ+) cells
represent the two major hematopoietic cell populations
that infiltrate spontaneous tumors in the RET model
(Lengagne et al., in preparation). However, HB-19 treat-
ment did not exert an apparent effect on the proportion
of myeloid and T cell populations infiltrating tumors in
the RET mice (Table 2).
During this study, no apparent behavior modifications
were noted in response to HB-19 treatment. Moreover,
when mice were sacrificed at the end of the study, autopsy
revealed no apparent effect on various tissues (including
lungs, liver, spleen, and kidney) of HB-19 treated com-
pared to control mice injected with PBS. One out of nine
mice treated with HB-19 (mouse N°5) died at day 219 in
the course of treatment (Table 1). This mouse displayed
no clinical signs of melanoma, thus suggesting a sponta-
neous death by an unexplained mechanism that might
occur although rarely even in control mice.
HB-19 treatment of melanoma-derived tumor cells
impairs their tumorigenic potential. Multiple passages
of TIII cells in the presence of HB-19 resulted in pro-
found effects on cell morphology without affecting signif-
icantly the multiplication index of cells. Intracellular
staining of actin allowed visualization of such morpho-
logical modifications between untreated and HB-19
treated cells (Figure 3). As expected, control TIII cells
proliferated without contact inhibition by crawling over
each other and with extensions characteristic of migra-
tion and/or invasion of tumorigenic cells as compared to
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Treatment Remarks in mice before autopsy 
(< Day 300)
Diagnosis at autopsy (Day 300)
Mice Regression Death Cutaneous tumor location and size (mm) Distant metastasis
Control 1 under eye 4, nose 3.1, under ear 4.9, back 6.7, 2.8 and 
2.9, thigh 5.9
Mediastinal
2 cheek 4.9, eye 6.2, under ear 5.4, 6.2, 7 and 5.7, back 
6.3 and 4.2, around genitals 3.8 and 4.7
None
3 cheek 3.3, under ear 6.7, around eye 6.3, back ear 3.5, 
back 3.2, thigh 5.1
Retroperitoneal
4 under eye 6.7 and 2.3, cheek 4.1 and 3, upper ear 2.8, 
under ear 3.4 and 5.6, leg 4.9 and 4.3, genitals 4
Retroperitoneal
5 under eye 11, 4 leg neighboring nodules 13.9 Visceral
6 upper eye 6.3, under eye 2.6, between ears 5.4 Retroperitoneal
7 cheek 2.9, nose 4.3, under ear 3.8, ear 4.7 Retroperitoneal
8 cheek 3.1, under eye 2.7 None
9 under ear 2.5, between eyes 3.8, under eye 6.3 and 3, 
leg 6.8, genitals 5.5, tail base 5.9
Retroperitoneal
10 cheek 5.6, 5.1, 3.4 and 3.7, under eye 7.4, leg 4.7, 
thigh 11.3
None
11 back ears 4.9, back 2.8, 1.9, 6.4, 3.5 and 2.2 Retroperitonel
HB-19 treated 1 under eye 6, cheek 3.5, around left eye 7.7, between 
ears 5, genitals 8, foot 9.2, tail 3.6
Visceral
2 under eye and thigh cheek 5.2 and 3, under eye 5, 3 nodules on the left 
cheek < 1, between ears 8.2, thigh 8.2, foot 7.9
Visceral
3 cheek 2.5, under ear 5.7, back 9.6, 5.5 and 3.2, thigh 6 Lung
4 Tumor free mouse None
5 dead D219* Tumor free mouse at day 219 None
6 Tumor free mouse None
7 cheek 1.4, under eye 3.9, back ears 6.4 None
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9 around eye 6.7 None
The particular aspects of the clinical diagnosis for the control (n = 11) and HB-19 treated (n = 9) RET mice are presented individually for each 
mouse. Column "Remarks in mice before autopsy" before day 300 gives tumor regression and natural death that occurred in HB-19 treated mouse 
2 and 5, respectively. Column "Diagnosis at autopsy" at day 300 gives the location of cutaneous tumors and their size measured with a caliper 
(the numbers next to each location correspond to the size of the tumor mass in mm), and metastasis occuring at distant locations, i.e., visceral 
metastasis as well as mediastinal adenopathies or lung metastasis (column "Distant metastasis"). Such non-cutaneous tumors were all 
chracterized by a large tumor mass (> 4 mm).
* Mouse N°5 died spontaneously at day 219 without symptoms of melanoma.
Table 1: Particular aspects of the clinical diagnosis for each control and HB-19 treated RET mice (Continued)
the HB-19 treated cells. On the other hand, HB-19 cul- centration. Following binding, HB-19 is internalized and
tured TIII cells appeared to be smaller in size with
rounded morphology, thus suggesting that HB-19 treat-
ment could affect their malignant phenotype. In accord
with this, the capacity of HB-19 precultured TIII cells to
form colonies in soft agar was significantly impaired (Fig-
ure 4A). For this purpose, cells were cultured in the
absence or presence of different concentrations of HB-19,
and then assayed for colony formation without further
addition of HB-19. Preculturing cells with HB-19 resulted
in a dose dependent reduction of the number of colonies,
reaching 56% inhibition when cells were precultured at 10
μM of HB-19.
To assess whether HB-19 can modify the tumorigenic
potential of TIII melanoma cells in vivo, MT/ret-/- mice
were injected subcutaneously with control and HB-19
precultured TIII cells. After 14 days, most of the mice
that received control TIII cells developed larger tumors
than mice that received HB-19 precultured cells (Figure
4B). The mean tumor mass in the control and HB-19
treated group was 91.4 ± 22.5 and 59.1 ± 15.8 mm2,
respectively. In order to illustrate the action of HB-19
treatment on metastasis, TIII cells were injected intrave-
nously in MT/ret-/- mice. The presence of lung metastasis
was assessed after 14 days during which time control and
HB-19 treated mice received daily intraperitoneal injec-
tions of PBS or HB-19, respectively. The results presented
in Figure 4C indicate that HB-19 treatment significantly
reduced the number of lung metastasis; the mean num-
ber of lung macro-metastases in the control and HB-19
treated group was 71 ± 5 and 41 ± 8, respectively.
An altered nuclear nucleolin pattern in cutaneous mel-
anocytic lesions observed by immunohistochemistry has
been associated with melanoma progression in patients
[33]. Indeed, immunofluorescence laser confocal micros-
copy studies on the melanoma TIII cells revealed the
presence of high number of nucleoli, which could account
for the observed nucleolin pattern in melanoma lesions.
Using biotinylated HB-19, we demonstrated that HB-19
binds surface nucleolin in a dose dependent manner in
the melanoma TIII cells reaching saturation at 4 μM con-
is concentrated in the cytoplasm without translocation
into the nucleus (data not presented). During this pro-
cess, there is specific reduction of surface/cytoplasmic
nucleolin without any apparent effect on the level of
nuclear nucleolin or its nucleolar distribution (similar to
the data presented in human breast cancer cells [10]).
This latter and the lack of an apparent effect on anchor-
age dependent cell proliferation suggest that the reduced
tumorigenicity of HB-19 treated TIII cells is not due to a
potential toxic effect of HB-19.
HB-19 treatment induces down regulation of specific 
transcripts coding genes associated with tumor cell 
invasion and metastasis
We investigated the expression of transcripts coding
MMP-2 and MMP-9 that degrade components of the
extracellular matrix [34], VEGF-A that triggers neovascu-
larization [35], TNF-α that contributes to all stages of the
malignant process [36], STAT-1 that regulates major cel-
lular events including tumorigenesis [37], MIA that is
associated with progression and metastasis of malignant
melanoma [38], and the housekeeping gene GAPDH as a
control. Expression of various transcripts was investi-
gated at 3-4 days post seeding of cells, since preliminary
experiments indicated that expression of MMP-2 and
MMP-9 mRNA is dependent on the cell density as it has
been reported previously [39]. Twenty-four hours after
HB-19 treatment, the level of transcripts coding MMP-2,
MMP-9, and TNF-α was markedly reduced in TIII cells at
10 μM HB-19, whereas these transcripts were completely
abolished at 25 μM HB-19. This is a selective effect, since
the expression of transcripts coding VEGF-A, STAT1,
MIA, and GAPDH seemed not to be affected by HB-19
treatment (Figure 5A). By quantitative RT-PCR, the
reduction of transcripts coding MMP-2, MMP-9, and
TNF-α was estimated to be > 90 and > 95% at 10 and 25
μM HB-19, respectively (data not shown). We next inves-
tigated the level of transcripts in HB-19 cultured TIII
cells after twelve passages, and in such HB-19 precul-
tured cells after further seven passages in the absence of
HB-19. The expression of transcripts coding MMP-2,
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cultured cells, whereas expression of the other genes was
not significantly affected (Figure 5B). Interestingly, the
expression of transcripts coding MMP-2, MMP-9, and
TNF-α remained markedly reduced in HB-19 precultured
TIII cells that were further passaged for 7-times in the
absence of HB-19 (Figure 5C). Consistent with these in
vitro results, the expression of transcripts coding MMP-2,
MMP-9, and TNF-α is similarly inhibited in the mela-
noma tumors recovered from HB-19 treated RET mice. A
typical example is presented in Figure 6 showing the
expression of various genes in tumors recovered from
HB-19 treated RET mice at the eye, ear and intraperito-
neum compared to tumors recovered from control RET
mice at similar locations, respectively.
Figure 1 HB-19 inhibits significantly spontaneous melanoma de-
velopment. RET mice were treated with HB-19 according to the 
schedule indicated in Methods and diagnosed frequently over a peri-
od of 300 days. A/B. HB-19 treatment delays significantly the onset of 
small cutaneous tumors (≥ 4 mm2) in panel A and of huge cutaneous 
tumors (> 60 mm2) in panel B (Log-rank Wilcoxon test, p < 0.001 for 
both graphs). The dotted lines correspond to data from untreated 
mice (n = 11) and full lines correspond to HB-19 treated mice (n = 9). 
C/D. HB-19 treatment significantly delays the incidence of facial (C) and 
dorsal (D) cutaneous nodules in RET mice. The dotted lines correspond 
to data from untreated mice and full lines correspond to HB-19 treated 
mice (Log-rank Wilcoxon test, p < 0.001). E/F. Number of facial (E) and 
dorsal (F) cutaneous nodules during the period of 120 days. The histo-
grams show the progression of the number of nodules (calculated for 
10 mice) in untreated (hatched bars) and HB-19 treated (black bars) 
mice, respectively. HB-19 treated mice displayed less cutaneous nod-
ules than untreated mice (p < 0.05 for both graphs).
Figure 2 Reduced density of blood vessels in tumors recovered 
from HB-19 treated RET mice. Sections of tumors from control un-
treated (panel A; localized under the ear) and HB-19 treated (panel B; 
localized under the eye) RET mice were stained with antibodies against 
the CD34 endothelial marker and analyzed by fluorescence microsco-
py (Methods). Representative macroscopic images (magnification 
200×) from each group of sections are presented. C. Quantification of 
angiogenesis was estimated by image analysis of CD34-labeled en-
dothelial cells in tumor sections from control and HB-19 treated RET 
mice. Statistical significance: * 0.01 < p < 0.1.
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The results presented herein demonstrate the antitu-
moral action of HB-19 in the transgenic RET mouse
model against development of spontaneous cutaneous
melanoma and visceral metastasis. We show that HB-19
treatment of 10 day old mice for a period of 10 months
causes a significant delay in the onset and the frequency
of large cutaneous tumors compared to untreated control
mice (Figure 1). In addition, HB-19 treatment exerts an
inhibitory effect on distant metastasis, since the fre-
quency of visceral metastasis was 72% and 33% in the
control and HB-19 treated mice, respectively (Table 1).
Furthermore, tumor vascularization is reduced signifi-
cantly in tumors recovered from HB-19 treated compared
to untreated control mice (Figure 2). These observations
illustrate the dual inhibitory action of HB-19 on tumor
cell growth and tumor angiogenesis, consistent with our
previous report using athymic nude mice with estab-
lished human breast tumor cell xenografts [10]. Fogal et
al [14] have recently reported that targeting surface
nucleolin with an antibody preparation against nucleolin
has no significant effect on tumor size or progression
while mediating a significant reduction of blood vessel
density. This difference in the mechanism of the antitu-
moral action of anti-nucleolin antibody compared to HB-
19 could be due to their mode of interaction with surface
nucleolin, since HB-19 binds the C-terminal RGG
domain [26] whereas the epitope of the anti-nucleolin
antibody is in the N-terminal acidic domain of nucleolin
[14].
In the melanoma derived TIII cells, we show that HB-
19 treated cells proliferate under contact inhibition and
loose partially their tumorigenic potential as demon-
strated by impaired colony formation in soft agar, and
reduced tumorigenicity and lung metastasis in MT/ret-/-
mice (Figures 3 and 4). Interestingly, HB-19 treatment
induces a specific down regulation of transcripts coding
MMP-2, MMP-9, and TNF-α in vitro in the TIII cells and
in vivo in tumors of HB-19 treated RET mice (Figure 5
and 6). Strikingly, the expression of these genes remains
down regulated in HB-19 pretreated TIII cells even after
seven passages in the absence of HB-19, thus suggesting
that HB-19 treatment could trigger differentiation of cul-
Table 2: HB-19 treatment does not modify the proportion of tumor infiltrating hematopoietic cells
Mice Mouse Number % CD45+ cells % CD11b+ cells % TCRαβ+ cells
Control 1 3.7 80.4 3.7
3 1.7 75.8 3.8
4 2.9 79.8 3.1
6 2.4 72.2 3.9
7 1.2 67.1 7.3
9 2.3 84.3 2.9
10 1.2 77.0 5.0
11 2.4 77.0 3.9
HB-19 treated 7 3.8 76.5 5.0
8 3.3 56.0 6.9
Single cell suspensions were prepared from pools of cutaneous tumors of mice that were still alive at day 300. FACS analysis of hematopoietic 
cells infiltrating melanoma tumors was carried using pooled suspension of various tumors in control and HB-19 treated mice (see Table 1 and 
Methods). Tumor infiltrating cells were stained with CD45/CD11b or with CD45/TcRαβ monoclonal antibodies.
Figure 3 Restoration of growth contact-inhibition in HB-19 cul-
tured TIII cells. TIII cells passaged 12-times in the absence or presence 
of 5 μM of HB-19 were fixed in PFA-Triton, and intracellular actin fila-
ments were stained with FITC-conjugated phalloidin. Immunofluores-
cence (A) and confocal (B) microscopy was as described in Methods.
El Khoury et al. BMC Cancer 2010, 10:325
http://www.biomedcentral.com/1471-2407/10/325
Page 9 of 12tured melanoma cells into a sub-population with some-
what stably reduced malignant phenotype. Consistent
with the results observed in melanoma TIII cells, we have
shown that HB-19 treatment impairs the tumorigenic
potential of several human epithelial tumor cells of differ-
ent origin, such as breast (MDA-MB-231, MDA-MB-
435), prostate (LNCaP), renal (G401), and colon (SW480,
SW620) carcinoma (manuscript in preparation). For
example, HB-19 treatment of G401 cells leads to restora-
tion of contact inhibition, specific down regulation of
several genes associated with tumorigenesis, and marked
reduction of tumorigenicity in the nude mice. Therefore,
the observed inhibitory action of HB-19 on the mela-
noma TIII cells is not specific for the rearranged RET-
driven melanoma [27,40]. The RET mice express rfp-ret
hybrid oncogene identified from a recombination event
in transfection assays carried on murine NIH 3T3 cells
[40]. Consequently, the potential role of RET as a human
oncogene remains to be demonstrated. Nevertheless, it is
interesting to note that activation of the intrinsic c-ret
proto-oncogene has recently been correlated with mela-
noma cell proliferation. Accordingly, the c-RET protein is
reported to be expressed in human melanomas while in
human malignant melanoma cell lines and in the RET
mice there is increased expression of c-RET transcripts
[31,41].
We recently reported that HB-19 can trigger rapid and
intense membrane Ca2+ fluxes in various types of tumor
cells by a mechanism that involves store-operated Ca2+
entry [8]. Consequently, HB-19 could be involved in the
activation of signaling pathways leading to regulation of
Figure 4 HB-19 affects the malignant phenotype of melanoma 
TIII cells. A. Reduced colony formation in soft agar. TIII cells were cul-
tured for twelve passages in the absence (control, histogram C) or 
presence of 1, 5 and 10 μM of HB-19 before assay for colony formation 
in the absence of further HB-19 treatment (***p < 0.001). B. Reduced 
tumorigenicity in mice. Tumor size was measured fourteen days after 
transplanting control (open circles, n = 14) or HB-19 precultured (black 
circles, n = 15) TIII cells. The graph corresponds to the results of two 
separate experiments. The mice transplanted with HB-19 precultured 
cells displayed tumors smaller than those treated with control cells 
(ANOVA, Mann Whitney test, p = 0.0276). C. Reduced lung metastasis 
in mice. Mice injected in the tail vein with TIII cells were treated (closed 
circles, n = 8) or not (open circles, n = 10) with HB-19, and the number 
of black lung macro-metastases was determined (ANOVA, Mann Whit-
ney test, p = 0.0014).
Figure 5 HB-19 treatment of TIII cells results in the reduction of 
transcripts coding MMP-2, MMP-9 and TNF-α. A. Expression of tran-
scripts 24 hours after HB-19 treatment. Two days after seeding, TIII cells 
were cultured for 24 hours in the absence (Control) or presence of 10 
or 25 μM of HB-19. B. Expression of transcripts in control and HB-19 cul-
tured TIII cells (cultured as described in Figure 3). C. Expression of tran-
scripts in control and HB-19 precultured TIII cells (as in section B) that 
were further passaged 7-times in the absence of HB-19. The expression 
of specific mRNAs was investigated by RT-PCR using primers for MMP-
2, MMP-9, VEGF-A, TNF-α, STAT-1, MIA and GAPDH.
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Page 10 of 12gene transcription. However, the mechanism responsible
for selective inhibition of MMP-2, MMP-9 and TNF-α
expression in HB-19 treated melanoma cells and tumors
remains to be elucidated. Matrix metalloproteinases are
extracellular proteinases associated with cancer invasion
and metastasis by virtue of degrading components of the
extracellular matrix [34], whereas proinflammatory
cytokines are indispensable participants in the neoplastic
process by orchestrating a tumor-supporting microenvi-
ronment [42]. Expression of MMP-2, MMP-9 and TNF-α
is strongly linked with malignant tumor progression,
angiogenesis and metastasis of various types of cancers
[43,44]. Consequently, the selective down regulation of
such strategic genes could account, at least in part, for the
mechanism of the antitumoral action of HB-19 in RET
mice. This is in accord with the results presented in Fig-
ure 1 and Table 1 showing a significant delay for the
development of spontaneous tumors and the reduced
incidence of visceral metastasis in HB-19 treated RET
mice compared to the corresponding controls. Although
the expression of transcripts coding various isoforms of
VEGF-A is not affected in HB-19 treated TIII cells (Fig-
ure 5), we have previously shown that HB-19 impairs sev-
eral VEGF induced endothelial functions involved in
angiogenesis by targeting surface nucleolin [10]. By its
capacity to block activation of endothelial cells therefore,
HB-19 could impair tumor vascularization in RET mice
(Figure 2). Taken together, these in vitro and in vivo stud-
ies provide new insights into the mechanism of antitumor
action of HB-19, and suggest that several inhibitory path-
ways could be operating in order to coordinate the delay
in the development of melanoma in HB-19 treated RET
mice. Recently, it was reported that infiltration of func-
tionally impaired CD8+ T cells, regulatory T cells, tolero-
genic dendritic cells and macrophages can occur within
metastatic melanoma lesions in patients [45-47]. We
found no profound alteration in the proportion of myel-
oid and T cell populations infiltrating tumors in HB-19
treated and related control RET mice. Consequently, it is
unlikely that the inhibitory effect of HB19 treatment is
due to the quantitative modulation of the tumor infiltrat-
ing immune cells. However, we cannot rule out the
potential implication of such hematopoietic cells in the
overall antitumoral action of HB-19.
HB-19 treatment significantly delays the development
of cancer in RET mice while displaying no toxicity to nor-
mal tissue. After binding surface nucleolin, HB-19 enters
cells by an active process but it does not cross the nuclear
membrane. Consequently, the effect of HB-19 is exerted
differentially and specifically via the cell surface
expressed nucleolin [10,26]. Although nuclear nucleolin
is involved in many aspects of gene expression [1,2], the
lack of translocation of HB-19 to the nucleus and nucleo-
lus could account, at least in part, for its lack of toxicity in
cultured cells and in animals. By studies on the pharma-
cokinetic and biodistribution properties of HB-19 in rats,
we have demonstrated that after preferential uptake of
HB-19 by specific tissues it is eliminated by renal glomer-
ular filtration in the form of HB-19 metabolites [15]. This
and the threshold for tissue uptake of HB-19 could pre-
vent prolonged accumulation of HB-19 in vivo, which
otherwise would lead to toxic effects [15]. Consistent
with this, no apparent toxicity was observed in the RET
mice that were treated over a period of 10 months with
HB-19. The molecular target of HB-19 in vitro and in vivo
is surface nucleolin that is expressed by activated and
proliferating cells [2,3,15,48]. In contrast to normal cells
however, nucleolin is constantly and abundantly
expressed on the surface of tumor cells making them a
preferential target for the inhibitory action of HB-19
(Hovanessian et al., submitted).
Conclusion
The growth and metastasis of solid tumors are dependent
on neovascularization in order to provide an appropriate
blood supply necessary for tumor cell proliferation and
Figure 6 Reduced expression of transcripts coding MMP-2, MMP-
9 and TNF-α in melanoma tumors recovered from HB-19 treated 
RET mice. The expression of transcripts coding MMP-2, MMP-9, VEGF-
A, TNF-α, STAT-1, MIA and GAPDH was investigated RT-PCR in tumors 
located at the eye, ear and intraperitoneum of control and HB-19 treat-
ed RET mice (as in Figure 5). The eye, ear and intraperitoneal tumors are 
representative for the firstly diagnosed nodule, a cutaneous nodule 
and a metastatic nodule, respectively. Equivalent tumor masses at sim-
ilar locations were considered for comparison.
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Page 11 of 12tumor invasion [49]. Although HB-19 treatment failed to
prevent the development of spontaneous melanoma in
the RET mice, it delayed significantly the onset and fre-
quency of cutaneous tumors, and reduced visceral metas-
tasis and tumor vascularization. Therefore, the inhibitory
action of HB-19 on tumor and endothelial cells as well as
on metastasis ([10] and the results herein) fulfills the cri-
teria as an efficient and a nontoxic drug for therapeutic
intervention in cancer. HB-19 could also be used as an
alternative therapy in cancer patients that develop resis-
tance to chemotherapy. Another advantage of HB-19 over
traditional anti-cancer drugs is its capacity to bind sur-
face nucleolin in an irreversible manner under physiolog-
ical conditions [26], making the half-life of tissue
associated HB-19 much longer compared to that of any
other cancer drug [15]. Finally, its reproducible synthesis,
stability in serum and in vivo lack of toxicity make HB-19
a unique drug against tumor growth and angiogenesis,
thus providing novel therapeutic opportunities in cancer
therapy by itself or as an adjuvant therapy in association
with current therapeutic interventions on a virulent can-
cer like melanoma.
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